Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Jun
04
Today In Oncology
Online Patient Resources About AI and Cancer Found Lacking
Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma
Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in Early Breast Cancer
Friends of Cancer Research Names Richard Pazdur, MD, to Board of Directors
Cochrane Review Finds Current Breast Cancer Risk Models Have Limited Accuracy in Women With a Family History of Disease
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo